Latest Belimumab Stories

GSK Pharma Acquires Human Genome Sciences For $3.6 Billion
2012-07-17 09:45:58

Lawrence LeBlond for redOrbit.com - Your Universe Online British pharmaceutical giant GlaxoSmithKline (GSK) has acquired US-based Human Genome Sciences (HGS) after tough negotiations saw it raise offers from an initial $2.6 billion in April, putting the final value of the deal at $3.6 billion or $14.25 per share. By securing HGS, GSK is gaining full control of the drug Benlysta, the first drug in more than 50 years to be approved by the Food and Drug Administration (FDA) for the...

2011-03-24 15:55:00

WASHINGTON, March 24, 2011 /PRNewswire/ -- Almost 3,000 walkers will celebrate the first drug developed for lupus in more than 50 years during the milestone 5th Annual Walk for Lupus Now! D.C. on Sat., April 16. Approved by the FDA on March 9, BENLYSTA by Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) represents relief for the unrelenting pain faced by many lupus patients whose disease still lacks a cure. American Idol-ready Devin Kowl (http://www.devinkowl.com/), a 15-year-old...

2011-03-10 14:23:13

The long path to Benlysta emphasizes importance of basic research Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues. "I am deeply gratified that our scientific...

2010-08-09 07:00:00

WALTHAM, Mass., Aug. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven primarily by the launch and uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, the systemic lupus erythematosus (SLE) drug market will quadruple from about $400 million in 2009 to more than $1.6 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor...

2010-02-01 07:00:00

WALTHAM, Mass., Feb. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected regulatory approval in 2011 in the United States and Europe, Human Genome Sciences/GlaxoSmithKline's Benlysta will garner sales of more than $500 million in 2018 in the systemic lupus erythematosus drug market. If approved, Benlysta will be the first agent to launch for systemic lupus erythematosus in...

2009-11-06 09:37:00

SCOTTSDALE, Ariz., Nov. 6 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies with a stake in the market for rheumatology therapies, including rheumatoid arthritis (RA) and lupus. "Of all the diseases rheumatologists treat, lupus still has the highest unmet need," according to MedPredict president Jeffrey Berk. "While many more people...

2009-11-02 01:18:00

BENLYSTA(TM) Successful in Second Pivotal Clinical Trial WASHINGTON, Nov. 2 /PRNewswire-USNewswire/ -- Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA(TM) (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology. Both trials succeeded in...

Word of the Day
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.